Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer

0
245

BOSTON– Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood’s Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood.

Mr. McCourt commented, “We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan’s deep financial and corporate strategy capabilities within the healthcare industry will help us continue to make a meaningful impact on the GI community and to our shareholders. We are very pleased that an executive with Sravan’s skills, integrity, and proven leadership is joining our leadership team.”

Mr. Emany brings an extensive array of financial experience to Ironwood, including a background in strategy, capital markets transactions, marketing, commercial support, and corporate leadership in the life sciences industry. Before joining Ironwood, Mr. Emany served as corporate vice president, commercial excellence and chief strategy officer of Integra LifeSciences Holdings Corporation, a publicly held global healthcare company where he also was vice president of strategy, treasury and investor relations.

Prior to this, Mr. Emany led numerous mergers and acquisitions in the healthcare sector and served in various investment banking roles for a total of 18 years at firms including Bank of America, Goldman Sachs, and Morgan Stanley. Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies (SAIS).

“I am inspired by Ironwood’s commitment to redefining the standard of care for GI diseases through continued scientific innovation,” added Mr. Emany. “I look forward to working with my new colleagues as we further strengthen Ironwood’s leadership position in GI to realize Ironwood’s long-term growth potential.”